Events

Investors



Webcast ImageWebcast
Rigel Pharmaceuticals FDA Approval of TAVALISSE (Replay)
April 17, 2018 at 5:00 p.m. ET
Webcast ImageWebcast
Q1 2018 Rigel Pharmaceuticals Earnings Call (Live)
May 1, 2018 at 2:00 p.m. PT

Corporate Profile

Rigel Pharmaceuticals, Inc. is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases.

Recent News

More »
DateTitle 
04/24/18Rigel Announces Conference Call and Webcast to Report First Quarter 2018 Financial Results
SOUTH SAN FRANCISCO, Calif., April 24, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its first quarter 2018 financial results after market close on Tuesday, May 1, 2018.  Rigel senior management will follow the announcement with a live conference call and webcast at 5:00pm Eastern Time (2:00pm Pacific Time) to discuss the financial results and provide a company update. Participants can access the live conference call by dialing 855-892-1489... 
Printer Friendly Version
04/19/18Rigel Announces Pricing Of Public Offering Of Common Stock
SOUTH SAN FRANCISCO, Calif., April 19, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the pricing of its previously announced underwritten public offering of 16,000,000 shares of its common stock, offered at a price of $3.90 per share to the public.  The gross proceeds to Rigel from this offering are expected to be $62.4 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Rigel.  All of the shares in t... 
Printer Friendly Version
04/18/18Rigel Announces Proposed Public Offering Of Common Stock
SOUTH SAN FRANCISCO, Calif., April 18, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it intends to offer and sell up to 15,000,000 shares of its common stock in an underwritten public offering. Rigel expects to grant the underwriters a 30-day option to purchase up to an additional 2,250,000 shares of common stock sold in the public offering on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assuranc... 
Printer Friendly Version

Upcoming Events

More »
Tuesday, May 1, 2018
 2:00 p.m. PT
Q1 2018 Rigel Pharmaceuticals Earnings Call

Stock Quote

RIGL (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$3.62
Change (%) + 0.02 (0.56%)
Volume65,702
Data as of 04/24/18 9:37 a.m. ET   Refresh quote

Stock Chart

Stock chart for: RIGL.O.  Currently trading at $3.62 with a 52 week high of $4.71 and a 52 week low of $2.14.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources

E-mail Alerts

Sign up to receive e-mail alerts whenever Rigel Pharmaceuticals Inc. posts new information to the site. Just enter your e-mail address and click Submit.